NTLA Description — Intellia Therapeutics Inc

Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. Co. utilizes its CRISPR/Cas9 platform across two areas: in vivo and ex vivo therapies. Co.'s in vivo candidate, NTLA-2001 for the treatment of transthyretin amyloidosis is the delivered CRISPR/Cas9-based therapy to enter clinical evaluation. Co.'s ex vivo applications to address immuno-oncology and autoimmune diseases.

Company Name: 
Intellia Therapeutics Inc
Number of ETFs Holding NTLA: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   NTLA Weight   NTLA Amount 
 VTI   0.02%   $244,195,681         
 VB   0.15%   $215,267,079         
 IWM   0.31%   $206,798,825         
 VBK   0.35%   $136,255,634         
 VXF   0.10%   $120,226,693         
 XBI   1.09%   $74,512,685         
 IWO   0.62%   $73,884,916         
 IBB   0.63%   $67,922,546         
 VHT   0.14%   $25,345,879         
 IDNA   5.67%   $18,586,468         
List of all 41 ETFs holding NTLA »
Quotes delayed 20 minutes

Buy (3.43 out of 4)
47th percentile
(ranked lower than approx. 53% of all stocks covered)

Analysts Forecast:
NTLA Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding NTLA | Intellia Therapeutics Inc | ETF Channel |

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.